Abstract
As stated previously, the purpose of the phase I oxidative activation reactions is to render xenobiotic compounds more soluble, more chemically reactive, and more easily excretable than the parent compound. Evolution has devised an ingenious mechanism for the removal of the metabolic products of the phase I detoxification reactions from cells. The mechanism involves two general steps. The first is a conjugation or coupling of the reactive intermediate with an endogenous carrier molecule, and the second is the elimination of the resulting conjugate out of the cell through the plasma membrane. The conjugation reactions, whereby a metabolite of a toxic agent (which may be more or less toxic than the parent compound) forms a covalent bond with the carrier molecule, are known as the phase II reactions. The resulting conjugates are almost always non-toxic, and because of certain properties of the carrier molecules, are easily eliminated from cells. There are only a few target carrier molecules in cells, the three most important being glucose, sulfate and glutathione. These compounds have the required attributes for serving the function of conjugation reactants. They are present in large concentrations in cells, which is vital, because for every molecule of toxicant eliminated, a molecule of carrier must also be lost. They are nucleophiles, which means that, like DNA and proteins, they can easily react with the electrophilic moieties generally found in toxic metabolites such as epoxides, diols, hydroxyls etc. Furthermore, they are themselves reactive molecules, and in their activated forms can pass through the plasma membrane thanks to specific transport systems. There is insufficient space here to expand further on the biochemistry of phase II conjugation reactions in general, which form an important area of biochemical toxicology. For the purpose of addressing how these reactions affect cancer susceptibility, the discussion will be restricted to glutathione, since the greater number of carcinogenic metabolites are eliminated by glutathione conjugation, and because the process has been extensively studied with respect to cancer susceptibility.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Antilla S, Luostarinenzz L, Hirvonenzz A, Elovaarazz E, Kalainenzz a, Nunninenzz T, Hayeszz JD, Vainiozz H, Ketterer B. (1995) Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: Association with GSTMI polymorphism, smoking and asbestos exposure. Cancer Research 55: 3305–3309.
Badavi A, Hirvonenzz A, Bellzz DA, Langzz N, Kadlubar FF. (1995) Role of aromatic amine acetyltransferases NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55: 5230–5237.
Bell DA, Jones P, Duncan H, Branniganzz K, Alldersea J, Fryer AA, Strange RC. (1996) Giutatlútransferase GSTTI genotypes and susceptibility to cancer: studies of interactions, with GSTMI in lung, oral, gastric and colorectal cancers. Carcinogenesis 17: 881–884.
Chen H, Sandierzz DP, Taylorzz JA, Shorezz DL, Liuzz E, Bloomfieldzz CD, Bell DA. (1996) Increased risk for myelodysplastic syndromes in individuate with-lutathione S-transferase theta 1 (GSTT I) gene defect. Lancet 347: 295–297.
Cmarik JL, Inskeepzz PB, Meredithzz MJ, Meyerzz DJ, Kettererzz B, Guengerich FP. (1990) Selectivity of rat and human glutathione S-transferases in activation of ethylene dibromide by glutathione conjugation and DNA binding and induction of unscheduled DNA synthesis in human hepatocytes. Cancer Res 50: 2747–2752.
D’Errico A, Taiolizz E, Xhenzz X, Vineis P. (1996) Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1: 149–173.
Feigelson HS, Coetzeezz GA, Kolonelzz LN, Rosszz RK, Henderson BE. (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Research 57: 1063–1065.
Hassett C, Aicherzz L, Sidhuzz JS, Omiecinski CJ. (1994) Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Human Molecular Genetics 3: 421–428.
Hirvonen A. (1998) “Polymorphic NATs and cancer proneness.” In Metabolic Polymorphisms and Cancer. P. Vineis M. Lang N. Caporaso J. Cuzick and P. Boffetta eds. IARC Publications, Lyon France.
Kelsey KT, Wienkezz JK, Ward J. (1995) Sister chromatid exchanges, glutathione-S-transferase T deletion and cytogenetic sensitivity to diepoxybutane in lymphocytes from butadiene monomer production workers. Mutat Res 335: 267–273.
Norppa H, Hirvonenzz A, Jarventauszz H, Uukulazz M, Tasazz G, Ojajarvizz A, Sorsa ivi. (1995) Role of GSTTI and GSTMI genotys in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cuitured human lymphocytes. Carcinogenesis 16: 1261–1264.
Rothman N, Traverzz RD, Smith MT. (1995) NADP(P): quinone oxidoreductase activity (NQ01) is associated with increased risk of benzene hematotoxicity. Proceedings of AACR 37: 258.
Schroeder KR, Wibelzz FA, Reichzz S, Dannappelzz D, Boltzz HM, Hallier E. (1995) Glutathione S-transferase (GST) theta poltmorphism influences background SCE rate. Arcíùves of Toxicology 69: 505–507.
Seidegard J, Voracheckzz WR, Perozz RW, Pearson WR. (1988) Hereditary differences in the expression of the human glutathione transferase activity on trans-stilbene oxide are due to a gene deletion. PNAS 85: 7293–7297.
Seidegard J, Perozz RW, Markowitzzz MM, Roushzz G, Millerzz DG, Beattie EJ. (1990) Isozymes of glutathione transferase (class mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 1: 33–36.
Strange RC, Fryer AA. “The glutatione S-transferases: influence of polymorphism on susceptibility to nonfamilial cancers.” In Metabolic Polymorphisms and Cancer. P. Vineis M. Lang N. Caporaso J. Cuzick and P. Boffetta eds. IARC Publications, Lyon France.
Taylor JA, Umbachzz D, Stephenszz E, Paulsonzz D, Robertsonzz C, Mohlerzz JL, Bell DA. (1995) Role of iv-acetylation polymorphism at IVATI and NAT2 in smoking associated bladder cancer. Proc Am Assoc Cancer Res 36: 282.
Thompson PA, Shieldszz PG, Freudenheimzz JL, Stonezz A, Venazz JE, Marshallzz JR, Grahamzz S, Laughlinzz R, Nemotozz T, Kadlubarzz FF, Ambrosone CB. (1998) Genetic polymorphisms in catechol-O-methyltransferase, menopausalzz status, and breast cancer risk. Cancer Research 58: 2107–2110.
Van Poppel G, De Vogel N, Sorsazz M, Castelyn L. (1992) Increased cytogenetic damage in smokers deficient in glutathione S-transferase isozyme p. Carcinogenesis 13: 303–305.
Vatsis KP, Weberzz WW, Bellzz DA, Dupretzz JM, Evanszz DAP, Grantzz DM, Heinzz DW, Linzz HJ, Meyerzz UA, Rellingzz MV, Simzz E, Suzukizz T, Yamazoe Y. (1995) Nomenclature for N-acetyltransferases. Pharmocgenetics 5: 1–17.
Vineis P, Ronco. (1992) Interindividual variation in carcinogen metabolism and bladder cancer risk. Environmental Health Perspectives 98: 95–99.
Wiencke JK, Kelseyzz KT, Lamelazz RA, Toscano Jr WA. (1990) Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Research 50: 1585–1590.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Garte, S. (1998). Phase II Metabolic Genes. In: Genetic Susceptibility to Cancer. Developments in Oncology, vol 79. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4989-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4989-5_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7265-3
Online ISBN: 978-1-4615-4989-5
eBook Packages: Springer Book Archive